Although anemia management was revolutionized in the 1980s with the introduction of recombinant human erythropoietin (EPO), adverse effects including worsening hypertension, seizures, dialysis access clotting, adverse cardiovascular events, and even increased risk of death, were noted in patients receiving erythropoiesis-stimulating agents (ESAs). This evidence concerns the gene EPO and hypertensive disorder.